{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:02:11Z","timestamp":1792116131121,"version":"4.4.0"},"reference-count":24,"publisher":"Wiley","issue":"4-5","license":[{"start":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T00:00:00Z","timestamp":1301011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["APMIS"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p>Olesen UH, Hastrup N, Sehested M. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas. APMIS 2011; 119: 296\u2013303.<\/jats:p><jats:p>The purpose of the study was to determine in human malignant lymphomas the expression patterns of nicotinamide phosphoribosyltransferase (NAMPT) and nicotinic acid phosphoribosyltransferase (NAPRT), the primary, rate\u2010limiting enzymes in the synthesis of NAD+. NAMPT is a potential biomarker for sensitivity to NAMPT inhibitors and NAPRT is a biomarker for the use of nicotinic acid as a chemoprotectant in treatment with NAMPT inhibitors. The NAMPT inhibitor, APO866, is currently in clinical phase II trials in lymphomas. The expression of NAMPT and NAPRT was investigated in 53 samples of malignant lymphomas (diffuse large B\u2010cell lymphoma, follicular B\u2010cell lymphoma, Hodgkin\u2019s lymphoma and peripheral T\u2010cell lymphoma). The expression of NAMPT was generally high in the more aggressive malignant lymphomas, with &gt;80% strong expression, whereas the expression in the more indolent follicular lymphoma (FL) was significantly lower (&gt;75% moderate or low expression, p\u2003=\u20030.0002). NAMPT was very highly expressed in Hodgkin Reed\u2010Sternberg cells in Hodgkin\u2019s lymphoma. NAPRT expression was more varied (p\u2003&gt;\u20030.0001) with 30\u201350% low expression except for Hodgkin\u2019s lymphoma where 85% displayed low expression (p\u2003=\u20030.0024). In conclusion, FL are a promising target for NAMPT inhibitors whereas substantial subsets of malignant lymphomas especially in Hodgkin lymphoma may be suitable for a combination treatment with nicotinic acid and NAMPT inhibitors.<\/jats:p>","DOI":"10.1111\/j.1600-0463.2011.02733.x","type":"journal-article","created":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T14:24:28Z","timestamp":1301063068000},"page":"296-303","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas"],"prefix":"10.1111","volume":"119","author":[{"given":"UFFE H\u00d8GH","family":"OLESEN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NINA","family":"HASTRUP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAXWELL","family":"SEHESTED","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,25]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20061638"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00035.2007"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2008.10.004"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161209787185814"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.7.4685"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.07.035"},{"key":"e_1_2_8_8_2","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis","volume":"63","author":"Hasmann M","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200111000-00005"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-173369"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.01.019"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00112-09"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-1130"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-677"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2009.03290.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.14.2.1431"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00194-7"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.22.12691"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/86318"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.022649799"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.294.5543.870"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064601"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.12.023"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-007-9083-2"}],"container-title":["APMIS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0463.2011.02733.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0463.2011.02733.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T05:23:01Z","timestamp":1693459381000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0463.2011.02733.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,25]]},"references-count":24,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1600-0463.2011.02733.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0463.2011.02733.x","archive":["Portico"],"relation":{},"ISSN":["0903-4641","1600-0463"],"issn-type":[{"value":"0903-4641","type":"print"},{"value":"1600-0463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,25]]},"assertion":[{"value":"2011-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}